Industrial Software’s Post

BLOG – Tailoring automation for tailored medicines. The #lifesciences industry is changing from being focused on mass-produced blockbuster drugs to personalized treatments like cell and gene therapies. This change requires companies to adopt flexible, targeted automation strategies instead of a one-size-fits-all approach. Emerson life sciences expert, Christian Berg discusses how these changes demand new, adaptable solutions in manufacturing and operations. Read the full blog . #software #analytics #mes http://emr.as/3j9w50T2kWu

Are you finding the path to commercializing cell and gene therapies complex and uncertain? Join us as we explore this intricate landscape with our guest, Wajiha Ali. Highlights: - Uncover the hurdles of patient referrals and manufacturing regulations, amplifying the complexity of these therapies. - Explore essential commercialization strategies and infrastructure needs while balancing innovation with necessity. -Learn about navigating regulatory scrutiny and stakeholder management for safer, more accessible therapies. What do you believe are the keys to facilitating the journey from scientific breakthroughs to real-world applications? #cellculture #processdevelopment #bioprocessing #celltherapymanufacturing #cellandgenetherapy #leadbiotech

What do you believe are the keys to facilitating the journey from scientific breakthroughs to real-world applications?

At the Economist Impact’s Cell and Gene Therapy (CGT) 2024 Summit, experts from across the industry discussed numerous topics and challenges in the introduction of CGTs: 📌 Regulatory 📌 Manufacturing and supply chain 📌 Clinical and scientific 📌 Commercial See the attached white paper capturing important themes and takeaways from the summit, including regulatory changes and new delivery models, the need to keep conversations and practices focused on patients, and how to structure clinical trials, gather real world evidence and streamline manufacturing to help improve access to treatment. #CellAndGeneTherapy #CGT #Innovation #biopharma #EconomistImpact #curiousminds Hannah Kurth

Are you ready for the next revolution in healthcare? Cell and gene therapies are poised to transform medicine as we know it. Biotech marketers and scientists face a common challenge: effectively communicating the complexities and potential of these groundbreaking therapies to stakeholders and the public. The technical nature of the field often creates barriers to understanding and engagement. Our latest blog breaks down the essentials of these innovative treatments. We explore the latest advancements, regulatory challenges, and future directions, providing you with a helpful overview of the landscape. Whether you're a marketer, scientist, or CEO, this knowledge will empower you to navigate the rapidly evolving world of cell and gene therapies with confidence. Read now: https://hubs.li/Q02KNPsG0 #BiotechMarketing #CellAndGeneTherapy #LifeScienceInnovation #Healthcare #PersonalizedMedicine

At the Economist Impact’s Cell and Gene Therapy (CGT) 2024 Summit, experts from across the industry discussed numerous topics and challenges in the introduction of CGTs: 📌 Regulatory 📌 Manufacturing and supply chain 📌 Clinical and scientific 📌 Commercial See the attached white paper capturing important themes and takeaways from the summit, including regulatory changes and new delivery models, the need to keep conversations and practices focused on patients, and how to structure clinical trials, gather real world evidence and streamline manufacturing to help improve access to treatment. #CellAndGeneTherapy #CGT #Innovation #biopharma #EconomistImpact #curiousminds

Modular facilities, driven by the rise of cell and gene therapies, continuous manufacturing, and single-use technologies, help biomanufacturers meet clinical demands. Learn how we partnered with Siemens to create automation and digitization solutions for streamlined modular processing. Watch the video below and learn more in our white paper: https://sar.to/1xs07 #SimplifyingProgress #InThisTogether #Bioprocessing

Rethinking ecosystems to enable access https://lnkd.in/etktvGiz Cell and gene therapy in the Asia-Pacific region. This update includes insights for overcoming the challenges of affordability and navigating healthcare systems in the Asia-Pacific region, especially in resource-constrained markets. It also explains why public-private partnerships and policy-shaping are key in building a future with optimal access to transformative cell and gene therapies in the region. https://lnkd.in/etktvGiz #HEOR #MarketAccess #WeAreAvalereHealth

Early Christmas miracle, "Fixing the Potholes in Cell and Gene Therapy" live here:https://lnkd.in/d_-KxZwr ALL 7 chapters. If you see or hear a better CGT discussion this year, it's proof positive you live in the multiverse, in some nearby neighborhood. HUGE thanks to Peter Marks Dir CBER, FDA Sean Hart, PhD CEO LumaCyte Fabian Gerlinghaus CEO Cellares and Fyodor Urnov Dir Innovative Genomics Institute Prof University of California, Berkeley . Among the many aspects considered, the panel discussed, what would it look like if we could use Prescriptive Analytics for Adaptive Manufacturing? How important are the starting materials in terms of outcomes? What role will gene editing play? What new delivery vectors are popular, and perhaps some not fully appreciated like perhaps Non-AAV parvoviruses or Herpes Simplex virus? Are analytics optimized or are there opportunities for big improvement? How can costs be decreased ? What barriers will need to be reduced over time, especially in terms of increasing patient access? There is even some new data (well, fairly new). Thanks also to BioPharm International Pharmaceutical Technology MJH Life Sciences® #cgt #AAV #oncoloy

SFBN Feed: The surprising outperformance of a new drug against existing competitors, and other biotech updates https://lnkd.in/gzCzPCVG Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see a gene therapy succeed in helping patients with a rare liver [...] #BayArea #SanFrancisco #Biotech #Lifescience #News